Cormorant Asset Management, LP I Teos Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$16.57 - $35.1 $1.66 Million - $3.51 Million	-100,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$31.92 - $47.45 $1.6 Million - $2.37 Million	-50,000 Reduced 33.33%	100,000 $3.22 Million
Q4 2021 Feb 14, 2022	SELL	$26.23 - $47.86 $3.63 Million - $6.62 Million	-138,330 Reduced 47.98%	150,000 $6.98 Million
Q2 2021 Aug 16, 2021	SELL	$17.9 - $36.1 $208,892 - $421,287	-11,670 Reduced 3.89%	288,330 $7.4 Million
Q4 2020 Feb 16, 2021	SELL	$21.59 - $33.95 $1.08 Million - $1.7 Million	-50,000 Reduced 14.29%	300,000 $10.1 Million

Q3 2020 Nov 16, 2020	BUY	$17.57 - $32.92 $6.15 Million - $11.5 Million	350,000 New	350,000 $8.64 Million

142

30.2M

84.6K

32.2K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $528M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.